Bone marrow suppression: Difference between revisions
m Task 18 (cosmetic): eval 3 templates: hyphenate params (1×); |
Updated Treatment section and added citations. |
||
| Line 40: | Line 40: | ||
===Chemotherapy induced myelosuppression=== |
===Chemotherapy induced myelosuppression=== |
||
Bone marrow suppression due to anti-cancer chemotherapy is much harder to treat and often involves hospital admission, strict infection control, and aggressive use of intravenous [[antibiotics]] at the first sign of infection.{{ |
Bone marrow suppression due to anti-cancer chemotherapy is much harder to treat and often involves hospital admission, strict infection control, and aggressive use of intravenous [[antibiotics]] at the first sign of infection.<ref>{{Cite journal|last=Al Sudairy|first=Reem|last2=Alzahrani|first2=Mohsen|last3=Alkaiyat|first3=Mohammad|last4=Alshami|first4=Mona|last5=Yaqub|first5=Abdullah|last6=Al Fayadh|first6=Maha|last7=Al-Surimi|first7=Khaled|last8=Jazieh|first8=Abdul Rahman|date=2019-08-01|title=Improving Door-to-Antibiotic Administration Time in Patients With Fever and Suspected Chemotherapy-Induced Neutropenia: A Tertiary Care Center Experience|url=https://meridian.allenpress.com/innovationsjournals-JQSH/article/2/3/78/434843/Improving-Door-to-Antibiotic-Administration-Time|journal=Global Journal on Quality and Safety in Healthcare|language=en|volume=2|issue=3|pages=78–84|doi=10.4103/JQSH.JQSH_1_19|issn=2666-2353}}</ref> |
||
[[G-CSF]] is used clinically (see [[Neutropenia]]) but tests in mice suggest it may lead to bone loss.<ref name=Dec2006>[http://news.wustl.edu/news/Pages/8512.aspx "Researchers urge monitoring of bone health during chemotherapy"].</ref><ref name="pmid17192391">{{cite journal |vauthors=Hirbe AC, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K | title = Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner | journal = Blood | volume = 109 | issue = 8 | pages = 3424–31 |date=April 2007 | pmid = 17192391 | pmc = 1852257 | doi = 10.1182/blood-2006-09-048686 }}</ref> |
[[G-CSF]] is used clinically (see [[Neutropenia]]) but tests in mice suggest it may lead to bone loss.<ref name=Dec2006>[http://news.wustl.edu/news/Pages/8512.aspx "Researchers urge monitoring of bone health during chemotherapy"].</ref><ref name="pmid17192391">{{cite journal |vauthors=Hirbe AC, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K | title = Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner | journal = Blood | volume = 109 | issue = 8 | pages = 3424–31 |date=April 2007 | pmid = 17192391 | pmc = 1852257 | doi = 10.1182/blood-2006-09-048686 }}</ref> |
||
[[GM-CSF]] has been compared to G-CSF as a treatment of chemotherapy-induced myelosuppression/[[Neutropenia]].<ref name="pmid9679526">{{cite journal |author=Beveridge RA |title=A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression |journal=Cancer Invest. |volume=16 |issue=6 |pages=366–373 |year=1998 |pmid=9679526 |doi=10.3109/07357909809115775 |name-list-style=vanc|author2=Miller JA |author3=Kales AN |display-authors=3 |last4=Binder |first4=Richard A. |last5=Robert |first5=Nicholas J. |last6=Harvey |first6=Jimmie H. |last7=Windsor |first7=Kevin |last8=Gore |first8=Ira |last9=Cantrell |first9=James}}</ref> |
[[GM-CSF]] has been compared to G-CSF as a treatment of chemotherapy-induced myelosuppression/[[Neutropenia]].<ref name="pmid9679526">{{cite journal |author=Beveridge RA |title=A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression |journal=Cancer Invest. |volume=16 |issue=6 |pages=366–373 |year=1998 |pmid=9679526 |doi=10.3109/07357909809115775 |name-list-style=vanc|author2=Miller JA |author3=Kales AN |display-authors=3 |last4=Binder |first4=Richard A. |last5=Robert |first5=Nicholas J. |last6=Harvey |first6=Jimmie H. |last7=Windsor |first7=Kevin |last8=Gore |first8=Ira |last9=Cantrell |first9=James}}</ref> |
||
Trilaciclib, a [[CDK inhibitor|CDK4/6 inhibitor]] under development by [[G1 Therapeutics]], administered before [[chemotherapy]] in [[Small-cell carcinoma|small cell lung cancer]], has in three clinical trials been shown to reduce bone marrow suppression and the need for supportive care interventions.<ref>{{Cite web|last=outsourcing-pharma.com|title=G1 Therapeutics: trilaciclib shows benefits for lung cancer patients|url=https://www.outsourcing-pharma.com/Article/2020/05/14/Trilaciclib-shows-promise-in-lung-cancer-trials|access-date=2021-01-01|website=outsourcing-pharma.com|language=en-GB}}</ref> |
|||
==Research== |
==Research== |
||
Revision as of 14:38, 1 January 2021
 | This article needs additional citations for verification. (July 2008) |
| Bone marrow suppression | |
|---|---|
| Other names | Myelotoxicity, myelosuppression |
| Specialty | Oncology |
Bone marrow suppression also known as myelotoxicity or myelosuppression, is the decrease in production of cells responsible for providing immunity (leukocytes), carrying oxygen (erythrocytes), and/or those responsible for normal blood clotting (thrombocytes).[1] Bone marrow suppression is a serious side effect of chemotherapy and certain drugs affecting the immune system such as azathioprine.[2] The risk is especially high in cytotoxic chemotherapy for leukemia.
Nonsteroidal anti-inflammatory drugs (NSAIDs), in some rare instances, may also cause bone marrow suppression. The decrease in blood cell counts does not occur right at the start of chemotherapy because the drugs do not destroy the cells already in the bloodstream (these are not dividing rapidly). Instead, the drugs affect new blood cells that are being made by the bone marrow.[3] When myelosuppression is severe, it is called myeloablation.[4]
Many other drugs including common antibiotics may cause bone marrow suppression. Unlike chemotherapy the effects may not be due to direct destruction of stem cells but the results may be equally serious. The treatment may mirror that of chemotherapy-induced myelosuppression or may be to change to an alternate drug or to temporarily suspend treatment.
Because the bone marrow is the manufacturing center of blood cells, the suppression of bone marrow activity causes a deficiency of blood cells. This condition can rapidly lead to life-threatening infection, as the body cannot produce leukocytes in response to invading bacteria and viruses, as well as leading to anaemia due to a lack of red blood cells and spontaneous severe bleeding due to deficiency of platelets.
Parvovirus B19 inhibits erythropoiesis by lytically infecting RBC precursors in the bone marrow and is associated with a number of different diseases ranging from benign to severe. In immunocompromised patients, B19 infection may persist for months, leading to chronic anemia with B19 viremia due to chronic marrow suppression.[5]
Treatment
Bone marrow suppression due to azathioprine can be treated by changing to another medication such as mycophenolate mofetil (for organ transplants) or other disease-modifying drugs in rheumatoid arthritis or Crohn's disease.
Chemotherapy induced myelosuppression
Bone marrow suppression due to anti-cancer chemotherapy is much harder to treat and often involves hospital admission, strict infection control, and aggressive use of intravenous antibiotics at the first sign of infection.[6]
G-CSF is used clinically (see Neutropenia) but tests in mice suggest it may lead to bone loss.[7][8]
GM-CSF has been compared to G-CSF as a treatment of chemotherapy-induced myelosuppression/Neutropenia.[9]
Trilaciclib, a CDK4/6 inhibitor under development by G1 Therapeutics, administered before chemotherapy in small cell lung cancer, has in three clinical trials been shown to reduce bone marrow suppression and the need for supportive care interventions.[10]
Research
In developing new chemotherapeutics, the efficacy of the drug against the disease is often balanced against the likely level of myelotoxicity the drug will cause. In-vitro colony forming cell (CFC) assays using normal human bone marrow grown in appropriate semi-solid media such as ColonyGEL have been shown to be useful in predicting the level of clinical myelotoxicity a certain compound might cause if administered to humans.[11] These predictive in-vitro assays reveal effects the administered compounds have on the bone marrow progenitor cells that produce the various mature cells in the blood and can be used to test the effects of single drugs or the effects of drugs administered in combination with others.
See also
- Hematopoietic stem cell transplantation
- Neutropenia, low leukocytes
References
- ^ "bone marrow suppression". Retrieved 3 May 2011.
- ^ Azathioprine side effects Archived November 25, 2010, at the Wayback Machine
- ^ Bone marrow suppression
- ^ Dictionary of Cancer Terms: myelosuppression
- ^ Parvovirus B19 - BASICS
- ^ Al Sudairy, Reem; Alzahrani, Mohsen; Alkaiyat, Mohammad; Alshami, Mona; Yaqub, Abdullah; Al Fayadh, Maha; Al-Surimi, Khaled; Jazieh, Abdul Rahman (2019-08-01). "Improving Door-to-Antibiotic Administration Time in Patients With Fever and Suspected Chemotherapy-Induced Neutropenia: A Tertiary Care Center Experience". Global Journal on Quality and Safety in Healthcare. 2 (3): 78–84. doi:10.4103/JQSH.JQSH_1_19. ISSN 2666-2353.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ "Researchers urge monitoring of bone health during chemotherapy".
- ^ Hirbe AC, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K (April 2007). "Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner". Blood. 109 (8): 3424–31. doi:10.1182/blood-2006-09-048686. PMC 1852257. PMID 17192391.
- ^ Beveridge RA, Miller JA, Kales AN, et al. (1998). "A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression". Cancer Invest. 16 (6): 366–373. doi:10.3109/07357909809115775. PMID 9679526.
- ^ outsourcing-pharma.com. "G1 Therapeutics: trilaciclib shows benefits for lung cancer patients". outsourcing-pharma.com. Retrieved 2021-01-01.
- ^ predicting-drug-induced-myelotoxicity